Vivace Therapeutics, Inc. logo

Vivace Therapeutics, Inc.

Vivace Therapeutics is developing small molecules Hippo-YAP pathway modulators as targeted therapies or immuno-oncology agents and bispecific antibodies to target cancer.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://vivacetherapeutics.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
2929 Campus Drive Suite 405, CA, 94403
San Mateo
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/vivace-therapeutics-inc-” connections=”true” suffix=””]

Vivace is targeting Hippo-YAP pathway, with first-in-class inhibitors that turn it off in cancers with activating mutations and activators that turn it on to enhance tumor immunogenicity in other cancers. Secondly, it is working on therapies based on antibodies called BINspecifics which are bi-specific irreversible non-covalent cell-type specific antibodies.These drugs hit cancer targets in specific and bind to them irreversibly.

In June 2017, Vivance raised $25 Mn Series B was led by new investor Cenova Capital and included Sequoia Capital China, Mission Bay Capital along with the exiting partners. Earlier in 2015, Canaan Partners and WuXi Healthcare Ventures co-led the companys $15 Mn Series A financing.